relapsed/refractory T cell acute lymphoblastic leukemia

$Experimental CAR T-Cell Therapy for Relapsed/Refractory ALL Patients Receives FDA Designations$

Experimental CAR T-Cell Therapy for Relapsed/Refractory ALL Patients Receives FDA Designations

Post author:Rose Duesterwald
Post published:August 10, 2022
Post category:Rare Disease

Targeted Oncology recently published an article describing a group of T cell malignancies associated with blood disorders (hematologic cancers). Currently, a high rate of patient deaths and relapses are occurring…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More